-
1Academic Journal
Authors: Yu. Glazyrin E., A. Shabalina V., K. Ryginskaya A., S. Zamay S., V. Kolovski A., V. Svetlichnyi A., I. Lapin N., G. Zamay S., O. Kolovskaya S., T. Zamay N., Yu. Pac S., A. Kichkailo S., Ю. Глазырин Е., А. Шабалина В., К. Рыжинская А., С. Замай С., В. Коловский А., В. Светличный А., И. Лапин Н., Г. Замай С., О. Коловская С., Т. Замай Н., Ю. Пац С., А. Кичкайло С.
Source: Bulletin of Siberian Medicine; Том 17, № 3 (2018); 13-21 ; Бюллетень сибирской медицины; Том 17, № 3 (2018); 13-21 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2018-17-3
Subject Terms: aptamers, biomarkers, lung cancer, multiplex electrochemical sensory system, аптамеры, биомаркеры, рак легкого, мультиплексная электрохимическая сенсорная система
File Description: application/pdf
Relation: https://bulletin.tomsk.ru/jour/article/view/1279/819; Mumbarkar P., Raste A.S., Ghadge M.S. Significance of tumor markers in lung cancer. Indian Journal of Clinical Biochemistry. 2006; 21 (1): 173–176. DOI:10.1007/BF02913090.; Wang R., Wang G., Zhang N., Li X., Liu Y. Clinical evaluation and cost-effectiveness analysis of serum tumor Markers in Lung Cancer. BioMed Research International. 2013; 2013: 1–7. DOI.org/10.1155/2013/195692.; Mizuguchi S., Nishiyama N., Iwata T., Nishida T., Izumi N., Tsukioka T., Inoue K., Kameyama M., Suehiro S. Cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Ann. Thorac. Surg. 2007; 83 (1): 216–221.; Bastawisy A.E., Elazzouny M., Mohammed G., Awadallah A., Behiry E. Serum cytokeratin 19 fragment in advanced lung cancer: could we eventually have a serum tumor marker? Ecancer. 2014; 8 (394): 1–9. DOI.org/10.3332/ecancer.2014.394.; Zamay G.S., Kolovskaya O.S., Zamay T.N., Glazyrin Yu.E., Krat A.V., Zubkova O.A., Spivak E.A., Wehbe M.B., Gargaun A.A., Muharemagic D.A., Komarova M.A., Grigorieva V.L., Savchenko A.A., Modestov A.A., Berezovski M.V., Zamay A.S. Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood. Molecular Тherapy. 2015; 23 (9): 1486–1496. DOI:10.1038/mt.2015.108.; Zamay G.S., Zamay T.N., Kolovskii V.A., Shabanov A.V., Glazyrin Yu.E., Veprintsev D.V., Krat A.V., Zamay S.S., Kolovskaya O.S., Gargaun A., Sokolov A.E., Modes- tov A.A., Artyukhov I.P., Chesnokov N.V., Petrova M.M., Berezovski M.V., Zamay A.S. Electrochemical aptasensor for lung cancer-related protein detection in crude blood plasma samples. Scientific Reports. 2016; 6: 343–350. DOI:10.1038/srep34350.; Berezovski M.V., Lechmann V., Musheev M.U., Mak T.W., Krylov S.N. Aptamer-facilitated biomarker discovery (AptaBID). Journal of American Chemical Society. 2008; 130 (28): 9137–9143. DOI:10.1021/ja801951p.; Василенко И.В., Кондратюк Р.Б., Колесникова И.А., Кудряшов А.Экспрессия виментина в опухолевых клетках раков различных органов и разного гистологического типа. Патология. 2014; 1 (30): 845–867.; Hou J.-M., Krebs M., Ward T., Sloane R., Priest L., Hughes A., Clack G., Ranson M., Blackhall F., Dive C. Circulating tumor cells as a window on metastasis biology in lung cancer. The American Journal of Pathology. 2011; 178 (3): 989–996. DOI:10.1016/j.ajpath.2010.12.003.; Satelli A., Li S. Vimentin as a potential molecular target in cancer therapy or Vimentin, an overview and its potential as a molecular target for cancer therapy. Cell Mol. Life Sci. 2011; 68 (18): 3033–3046. DOI:10.1007/s00018-011-0735-1.; Al-Saad S., Al-Shibli K., Donnem T., Persson M., Bremnes R.M., Busund L.-T. The prognostic impact of NF-kB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. British Journal of Cancer. 2008; 99 (9): 1476–1483. DOI:10.1038/sj.bjc.6604713.; Paterlini-Brechot P., Benali N.L. Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Letters. 2007; 253 (2): 180–204. https://doi.org/10.1016/j.canlet.2006.12.014.; Arimura Y., Ashitani J.-I., Yanagi S., Tokojima M., Abe K., Mukae H., Nakazato M. Elevated serum-defensins concentrations in patients with lung cancer. Anticancer Research. 2004; 24: 4051–4058.; Tomlinson V.A., Newbery H.J., Bergmann J.H., Boyd J., Scott D., Wray N.R., Sellar G.C., Gabra H., Graham A., Williams A.R., Abbott C.M. Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus. British J. Cancer. 2007; 96 (10): 1613–1620. DOI:10.1038/sj.bjc.6603748.; Pinke D.E., Kalloger E., Francetic T., Huntsman D.G., Lee J.M. The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol. Oncol. 2008; 108 (3): 561–568. DOI:10.1016/j.ygyno.2007.11.019.; Cao H., Zhu Q., Huang J., Li B., Zhang S., Yao W., Zhang Y. Regulation and functional role of eEF1A2 in pancreatic carcinoma. Biochem. Biophys. Res. Commun. 2009; 380 (1): 11–16. DOI:10.1016/j.bbrc.2008.12.171.; Li Z., Qi C.F., Shin D.M., Zingone A., Newbery H.J., Kovalchuk A.L., Abbott C.M., Morse H.C. Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/ STAT and AKT signaling in mouse plasmacytomas. PLoS One. 2010; 5 (5): e10755. https://doi.org/10.1371/journal.pone.0010755.; Blanch A., Robinson F., Watson I.R., Cheng L. S., Irwin M.S. Eukaryotic translation elongation factor 1-Alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity. Plos One. 2013; 8 (6): e66436. https://doi.org/10.1371/journal.pone.0066436.; Kenzo K., Kaneko K., Satoh K., Masamune A., Satoh A., Shimosegawa T. Myosin light chain kinase inhibitors can block invasion and adhesion of human pancreatic cancer cell lines. Pancreas. 2002; 24 (1): 34–41.; Joglekar A.P., Bloom K.S., Salmon E.D. Mechanisms of force generation by end-on kinetochore-microtubule attachments. Current Opinion in Cell Biology. 2010; 22 (1): 57–67. https://doi.org/10.1016/j.ceb.2009.12.010.; Martello L.A., Verdier-Pinard P., Shen H.-J., He L., Torres K., Orr G. A., Horwitz S. B. Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent a549 cell line with an α-tubulin mutation. Cancer Res. March. 2003; 63: 1207.; Lee W.L., Downey G.P. Leukocyte elastase: physiological functions and role in acute lung injury. Am. J. Respir. Crit. Care Med. 2001; 164 (5): 896–904. DOI:10.1164/ajrccm.164.5.2103040.; Houghton A.M., Rzymkiewicz D.M., Ji H., Gregory A.D., Egea E.E., Metz H.E. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat. Med. 2010; 16 (2): 219–223. DOI:10.1038/nm.2084.; https://bulletin.tomsk.ru/jour/article/view/1279
-
2Academic Journal
Authors: Yu. E. Glazyrin, A. V. Shabalina, K. A. Ryginskaya, S. S. Zamay, V. A. Kolovski, V. A. Svetlichnyi, I. N. Lapin, G. S. Zamay, O. S. Kolovskaya, T. N. Zamay, Yu. S. Pac, A. S. Kichkailo
Source: Бюллетень сибирской медицины, Vol 17, Iss 3, Pp 13-21 (2018)
Subject Terms: аптамеры, биомаркеры, рак легкого, мультиплексная электрохимическая сенсорная система, Medicine
Relation: https://bulletin.ssmu.ru/jour/article/view/1279; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/c9d621bd59334e3181d5098044cae263
-
3Academic Journal
Authors: Глазырин, Юрий Евгеньевич, Шабалина, Анастасия Валерьевна, Рыжинская, Ксения Александровна, Замай, Сергей Сергеевич, Коловский, Василий Андреевич, Светличный, Валерий Анатольевич, Лапин, Иван Николаевич, Замай, Галина Сергеевна, Коловская, Ольга Сергеевна, Замай, Татьяна Николаевна, Пац, Юрий Сергеевич, Кичкайло, Анна Сергеевна
Source: Бюллетень сибирской медицины. 2018. Т. 17, № 3. С. 13-21
Subject Terms: аптамеры, биомаркеры, рак легкого, мультиплексная электрохимическая сенсорная система
File Description: application/pdf
Relation: http_0185-79260. Бюллетень сибирской медицины; koha:001158003; https://vital.lib.tsu.ru/vital/access/manager/Repository/koha:001158003